Five-Year Follow-up of the Plaque Sealing With Paclitaxel-Eluting Stents vs Medical Therapy for the Treatment of Intermediate Nonobstructive Saphenous Vein Graft Lesions (VELETI) Trial

Canadian Journal of Cardiology

Volumn 30, Issue 1, 2014, Pages 138-145

  Rodés Cabau, Josep ^a   Bertrand, Olivier F ^a   Larose, Eric ^a   Déry, Jean Pierre ^a   Rinfret, Stéphane ^a   Urena, Marina ^a   Jerez, Miguel ^a   Nombela Franco, Luis ^a   Ribeiro, Henrique B ^a   Allende, Ricardo ^a   Proulx, Guy ^a   Nguyen, Can M ^a   Boudreault, Jean Rock ^a   Rouleau, Jacques ^a   Roy, Louis ^a   Gleeton, Onil ^a   Barbeau, Gérald ^a   Noël, Bernard ^a   CÔté, Mélanie ^a   Després, Jean Pierre ^a   Dagenais, Gilles R ^a   DeLarochellière, Robert ^a   more..

^a LAVAL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; PACLITAXEL;

ACUTE CORONARY SYNDROME; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DISEASE COURSE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; IN-STENT RESTENOSIS; INTERVENTIONAL CARDIOVASCULAR PROCEDURE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; OUTCOME ASSESSMENT; PILOT STUDY; PLAQUE SEALING; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); UNSTABLE ANGINA PECTORIS; VEIN GRAFT DISEASE;

EID: 84890819886     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2013.11.002     Document Type: Article

References (18)

1. Goldman S., Zadina K., Moritz T., et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. JAm Coll Cardiol 2004, 44:2149-2156.
2. Domanski M.J., Borkowf C.B., Campeau L., et al. Prognostic factors for atherosclerosis progression in saphenous vein grafts. JAm Coll Cardiol 2000, 36:1877-1883.
3. Ellis S.G., Brener S.J., DeLuca S., et al. Late myocardial ischemic events after saphenous vein graft intervention: importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 1997, 79:1460-1464.
4. Rodés-Cabau J., Facta A., Larose E., et al. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting. Am J Cardiol 2007, 100:640-645.
5. Knatterud G.L., White C., Geller N.L., et al. Angiographic changes in saphenous vein grafts are predictors of clinical outcomes. Am Heart J 2003, 145:262-269.
6. Le May M.R., Labinaz M., Marquis J.F., et al. Predictors of long-term outcome after stent implantation in a saphenous vein graft. Am J Cardiol 1999, 83:681-686.
7. Lytle B.W., Loop F.D., Taylor P.C., et al. Vein graft disease: the clinical impact of stenoses in saphenous vein grafts to coronary arteries. JThorac Cardiovasc Surg 1992, 103:831-840.
8. Rodés-Cabau J., Bertrand O.F., Larose E., et al. Comparison of plaque sealing with paclitaxel-eluting stents versus medical therapy for the treatment of moderate nonsignificant saphenous vein graft lesions: the moderate vein graft lesion stenting with the taxus stent and intravascular ultrasound (VELETI) pilot trial. Circulation 2009, 120:1978-1986.
9. Abdel-Karim A.R., Da Silva M., Lichtenwalter C., et al. Prevalence and outcomes of intermediate saphenous vein graft lesions: findings from the stenting of saphenous vein grafts randomized-controlled trial. Int J Cardiol 2013, 168:2468-2473.
10. Cutlip D.E., Windecker S., Mehran R., et al. Clinical end points in coronary stent trials. A case for standardized definitions. Circulation 2007, 115:2344-2351.
11. Mehilli J., Pache J., Abdel-Wahab M., et al. Drug-eluting versus bare-metal stents in saphenous vein graft lesions (ISAR-CABG): a randomised controlled superiority trial. Lancet 2011, 378:1071-1078.
12. Brilakis E.S., Lichtenwalter C., de Lemos J.A., et al. Arandomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial. JAm Coll Cardiol 2009, 53:919-928.
13. Vermeersch P., Agostoni P., Verheye S., et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. JAm Coll Cardiol 2006, 48:2423-2431.
14. Brilakis E.S., Lichtenwalter C., Abdel-karim A.R., et al. Continued benefit from paclitaxel-eluting compared with bare-metal stent implantation in saphenous vein graft lesions during long-term follow-up of the SOS (Stenting of Saphenous Vein Grafts) trial. JACC Cardiovasc Interv 2011, 4:176-182.
15. Vermeersch P., Agostoni P., Verheye S., et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. JAm Coll Cardiol 2007, 50:261-267.
16. Habara M., Terashima M., Nasu K., et al. Morphological differences of tissue characteristics between early, late, and very late restenosis lesions after first generation drug-eluting stent implantation: an optical coherence tomography study. Eur Heart J Cardiovasc Imaging 2013, 14:276-284.
17. Keeley E.C., Velez C.A., O'Neill W.W., Safian R.D. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. JAm Coll Cardiol 2001, 38:659-665.
18. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary-artery bypass grafts. NEngl J Med 1997, 336:153-162. Post Coronary Artery Bypass Graft Trial Investigators.